Biologics CDMO Market Growth Outlook Reveals A CAGR Of 14.9% And A Market Value Of $48.06 Billion By 2030
Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Biologics CDMO Market Value Analysis: What Growth Is Expected Over The Forecast Period?
The biologics CDMO market has experienced swift expansion in recent years, with projections indicating an increase from $24.15 billion in 2025 to $27.56 billion in 2026, reflecting a compound annual growth rate (CAGR) of 14.1%. This historical growth has been driven by factors including heightened biologics research, progress in cell culture techniques, a rising incidence of chronic illnesses, expansion of biosimilar development efforts, and governmental backing for biopharmaceutical production.
The biologics CDMO market is forecasted to experience substantial expansion over the coming years. Its value is projected to reach $48.07 billion by 2030, reflecting a compound annual growth rate (CAGR) of 14.9%. This anticipated growth during the forecast period is driven by a surge in the development of gene and cell therapies, the growing implementation of automation and robotics within CDMO operations, the increase in global manufacturing capabilities for biologics, heightened investment in precision medicine, and a rising need for cost-effective biologic solutions. Key developments expected in this period include the broadening of biologics CDMO offerings, a rise in mammalian cell-based production, greater outsourcing of gene therapy manufacturing, the adoption of cutting-edge bioprocessing methods, and an escalating demand for biosimilars.
Download A Free Sample Report For Comprehensive Market Insights:
#Biologics CDMO Market Growth Factors: Which Forces Are Supporting Market Expansion?
The growing need for cell and genetic therapies is expected to boost the biologic CDMO market moving forward. These treatment approaches use living cells or genetic material to target disease causes at a cellular or genetic level, offering hope for conditions that are hard to treat or incurable with standard drugs. Rising demand stems from their ability to provide novel solutions for diseases by tackling root genetic or cellular issues. Biologic CDMOs bring specialized skills in managing live cells, viral vectors, and genetic components, ensuring safe and effective production of these therapies while helping biopharma firms meet regulatory hurdles and technical obstacles, thus easing the shift from research to clinical use. For example, in March 2024, IQVIA Holdings Inc., a US-based firm offering advanced analytics, tech solutions, and clinical research services for life sciences and healthcare, reported that global spending on cell and gene therapies hit $5.9 billion in 2023, a 38% jump from 2022. Consequently, the rising demand for cell and gene therapy is fueling growth in the biologic CDMO market.
Biologics CDMO Market Segment Analysis: What Are The Major Market Categories?
The biologics cdmo market covered in this report is segmented –
1) By Cell Type: Mammalian, Non-Mammalian
2) By Product Type: Biologics, Biosimilars
3) By Service Type: Drug Substance Manufacturing, Drug Product (Fill–Finish) Manufacturing, Process Development, Analytical & Quality Testing Services
Subsegments:
1) By Mammalian: Chinese Hamster Ovary (CHO) Cells, Human Embryonic Kidney (HEK) Cells, Other Mammalian Cells
2) By Non-Mammalian: Yeast Cells, Bacterial Cells, Insect Cells, Other Non-Mammalian Cells
Biologics CDMO Market Industry Trends: What Changes Are Reshaping Demand?
Major players in the biologics contract development and manufacturing organization (CDMO) market are rolling out highly advanced technological solutions, including novel cell lines, aimed at boosting the efficiency and capabilities of biopharmaceutical development and production. This technology enables the creation of therapeutic antibodies with greater potency, addressing persistent challenges in immunotherapy research and development. For example, in November 2023, Lonza Group, a Swiss contract manufacturing firm focusing on the pharmaceutical and biotech sectors, introduced its GS Effex cell lines. These are specifically engineered to generate completely fucose-free antibodies, thereby enhancing their potency without sacrificing performance in other areas. This innovation helps meet the need for more effective antibody therapeutics in immunotherapy research. The cell line is stable, scalable, and productive, offering a complete solution for therapeutic development ranging from early discovery all the way to commercial-scale manufacturing.
Biologics CDMO Market Leading Companies Driving Competitive Growth
Major companies operating in the biologics cdmo market are Lonza Group Ltd, Samsung Biologics Co Ltd, WuXi Biologics Cayman Inc, Catalent Inc, Thermo Fisher Scientific Inc, Boehringer Ingelheim International GmbH, Emergent BioSolutions Inc, Grifols SA, AbbVie Inc, Novartis AG, Sandoz International GmbH, Fujifilm Holdings Corporation, AGC Inc, JSR Corporation, Shenzhen Hepalink Pharmaceutical Co Ltd, Kemwell Biopharma Pvt Ltd, Bora Pharmaceuticals Co Ltd, Binex Co Ltd, 3P Biopharmaceuticals SLU, Cytovance Biologics
Access The Complete Biologics CDMO Market Report:
Biologics CDMO Market Leading Geography: Which Region Generates The Most Revenue?
North America was the largest region in the biologics CDMO market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biologics cdmo market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
